A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
A phase 3 trial of Talquetamab, Daratumumab, Pomalidomide in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment is a phase 3 interventional study registered as NCT05455320 by Janssen Research & Development, LLC, with 864 participants enrolled, started 2022-10-13 and due to reach its primary completion in 2027-07-30. Interventions recorded: Talquetamab, Daratumumab, Pomalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal
Shares Talquetamab, Daratumumab, Dexamethasone, Johnson & Johnson.
- TrialA Study of Daratumumab
Shares Pomalidomide, Daratumumab, Dexamethasone, Johnson & Johnson.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez
Shares Talquetamab, Pomalidomide, Dexamethasone, Johnson & Johnson.
- TrialA Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.